Early T-cell precursor lymphoblastic leukemia accompanied by prominent blastic plasmacytoid dendritic cell proliferation mimicking blastic plasmacytoid dendritic cell neoplasm: an exceptional case report and literature review.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Blastic plasmacytoid dendritic cell proliferation
Early T-cell precursor lymphoblastic leukemia (ETP-ALL)
Immunophenotype
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
02
03
2022
accepted:
25
07
2022
pubmed:
7
8
2022
medline:
16
9
2022
entrez:
6
8
2022
Statut:
ppublish
Résumé
Plasmacytoid dendritic cells (pDCs) are commonly associated with myeloid malignancies. The association between lymphoblastic leukemia and pDCs has been little explored. Here, we report a novel case of early T-cell precursor lymphoblastic leukemia (ETP-ALL) accompanied by prominent proliferation of blastic pDCs mimicking BPDCN. The diagnosis was established based on a comprehensive analysis of morphology, immunophenotype and clinical implications. We also present a literature review and discussion on the differential expression of reactive and neoplastic pDCs, the functional role of pDCs in lymphoblastic leukemia, and the etiological association of normal pDCs and BPDCN. The current case demonstrates for the first time that prominent pDC proliferation can be associated with lymphoid neoplasms and can exhibit blastic morphology and immunophenotype. The underlying mechanism of the coexistence of these two blastic populations remains unknown. Further genetic profiling may be required to denote the progressive development of tumor stem cells to the lymphoid, myeloid or dendritic cell lineage. Moreover, the prognostic value of pDCs in hematological neoplasms needs further investigation.
Identifiants
pubmed: 35933443
doi: 10.1007/s00432-022-04238-0
pii: 10.1007/s00432-022-04238-0
doi:
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2911-2919Subventions
Organisme : National Natural Science Foundation of China
ID : 81902129
Organisme : Department of Science and Technology of Sichuan Province
ID : 2019YFS0321
Organisme : Department of Science and Technology of Sichuan Province
ID : 2019YFS0313
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N et al (2013) TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 88(12):1055–1061. https://doi.org/10.1002/ajh.23567
doi: 10.1002/ajh.23567
pubmed: 23940084
Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T et al (2017) Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study. J Clin Oncol off J Am Soc Clin Oncol 35(23):2683–2691. https://doi.org/10.1200/JCO.2016.71.8585
doi: 10.1200/JCO.2016.71.8585
Cordeau M, Belounis A, Lelaidier M, Cordeiro P, Sartelet H, Herblot S et al (2016) Efficient killing of high risk neuroblastoma using natural killer cells activated by plasmacytoid dendritic cells. PLoS One 11(10):e0164401. https://doi.org/10.1371/journal.pone.0164401
doi: 10.1371/journal.pone.0164401
pubmed: 27716850
pmcid: 5055353
Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L et al (2010) Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol 34(1):75–87. https://doi.org/10.1097/PAS.0b013e3181c5e26b
doi: 10.1097/PAS.0b013e3181c5e26b
pubmed: 19956058
Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D et al (2009) Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10(2):147–156. https://doi.org/10.1016/S1470-2045(08)70314-0
doi: 10.1016/S1470-2045(08)70314-0
pubmed: 19147408
pmcid: 2840241
Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P et al (2010) Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 162(1):74–79. https://doi.org/10.1111/j.1365-2133.2009.09373.x
doi: 10.1111/j.1365-2133.2009.09373.x
pubmed: 19689477
Dargent JL, Delannoy A, Pieron P, Husson B, Debecker C, Petrella T (2011) Cutaneous accumulation of plasmacytoid dendritic cells associated with acute myeloid leukemia: a rare condition distinct from blastic plasmacytoid dendritic cell neoplasm. J Cutan Pathol 38(11):893–898. https://doi.org/10.1111/j.1600-0560.2011.01777.x
doi: 10.1111/j.1600-0560.2011.01777.x
pubmed: 21883371
Derolf AR, Laane E, Bjorklund E, Saft L, Bjorkholm M, Porwit A (2014) Dendritic cells in bone marrow at diagnosis and after chemotherapy in adult patients with acute myeloid leukaemia. Scand J Immunol 80(6):424–431. https://doi.org/10.1111/sji.12223
doi: 10.1111/sji.12223
pubmed: 25346147
Diaz-Rodriguez Y, Cordeiro P, Belounis A, Herblot S, Duval M (2017) In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells. Cancer Immunol Immunother 66(10):1307–1320. https://doi.org/10.1007/s00262-017-2022-y
doi: 10.1007/s00262-017-2022-y
pubmed: 28555259
pmcid: 5626790
Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W (2016) Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol off J U S Can Acad Pathol Inc 29(2):98–111. https://doi.org/10.1038/modpathol.2015.145
doi: 10.1038/modpathol.2015.145
Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L et al (2002) Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 99(5):1556–1563. https://doi.org/10.1182/blood.v99.5.1556
doi: 10.1182/blood.v99.5.1556
pubmed: 11861268
Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE et al (2014) Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 124(3):385–392. https://doi.org/10.1182/blood-2014-04-566737
doi: 10.1182/blood-2014-04-566737
pubmed: 24859366
pmcid: 4260361
Fu Y, Fesler M, Mahmud G, Bernreuter K, Jia D, Batanian JR (2013) Narrowing down the common deleted region of 5q to 6.0 Mb in blastic plasmacytoid dendritic cell neoplasms. Cancer Genet 206(7–8):293–298. https://doi.org/10.1016/j.cancergen.2013.07.002
doi: 10.1016/j.cancergen.2013.07.002
pubmed: 24042168
Gabrilovich D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4(12):941–952. https://doi.org/10.1038/nri1498
doi: 10.1038/nri1498
pubmed: 15573129
Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ (1997) The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 185(6):1101–1111. https://doi.org/10.1084/jem.185.6.1101
doi: 10.1084/jem.185.6.1101
pubmed: 9091583
pmcid: 2196227
Harvell JD, Fulton R, Jones CD, Terris DJ, Warnke RA (2000) Composite dendritic cell neoplasm (NOS) and small lymphocytic lymphoma. Appl Immunohistochem Mol Morphol 8(4):322–328
pubmed: 11127925
Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D (2003) TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 101(12):5007–5009. https://doi.org/10.1182/blood-2002-10-3297
doi: 10.1182/blood-2002-10-3297
pubmed: 12576313
Ishikawa F, Niiro H, Iino T, Yoshida S, Saito N, Onohara S et al (2007) The developmental program of human dendritic cells is operated independently of conventional myeloid and lymphoid pathways. Blood 110(10):3591–3660. https://doi.org/10.1182/blood-2007-02-071613
doi: 10.1182/blood-2007-02-071613
pubmed: 17664352
pmcid: 2077309
Jain N, Lamb AV, O’Brien S, Ravandi F, Konopleva M, Jabbour E et al (2016) Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood 127(15):1863–1869. https://doi.org/10.1182/blood-2015-08-661702
doi: 10.1182/blood-2015-08-661702
pubmed: 26747249
pmcid: 4915808
Jegalian AG, Facchetti F, Jaffe ES (2009) Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol 16(6):392–404. https://doi.org/10.1097/PAP.0b013e3181bb6bc2
doi: 10.1097/PAP.0b013e3181bb6bc2
pubmed: 19851130
pmcid: 6329307
Jing Y, Shaheen E, Drake RR, Chen N, Gravenstein S, Deng Y (2009) Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum Immunol 70(10):777–784. https://doi.org/10.1016/j.humimm.2009.07.005
doi: 10.1016/j.humimm.2009.07.005
pubmed: 19596035
pmcid: 5718338
Julia F, Dalle S, Duru G, Balme B, Vergier B, Ortonne N et al (2014) Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol 38(5):673–680. https://doi.org/10.1097/PAS.0000000000000156
doi: 10.1097/PAS.0000000000000156
pubmed: 24441662
Karsunky H, Merad M, Mende I, Manz MG, Engleman EG, Weissman IL (2005) Developmental origin of interferon-alpha-producing dendritic cells from hematopoietic precursors. Exp Hematol 33(2):173–181. https://doi.org/10.1016/j.exphem.2004.10.010
doi: 10.1016/j.exphem.2004.10.010
pubmed: 15676211
Khan AM, Munir A, Raval M, Mehdi S (2019) Blastic plasmacytoid dendritic cell neoplasm in the background of myeloproliferative disorder and chronic lymphocytic leukaemia. BMJ Case Rep. https://doi.org/10.1136/bcr-2019-230332
doi: 10.1136/bcr-2019-230332
pubmed: 31892623
pmcid: 6954789
Khoury JD, Medeiros LJ, Manning JT, Sulak LE, Bueso-Ramos C, Jones D (2002) CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer 94(9):2401–2408. https://doi.org/10.1002/cncr.10489
doi: 10.1002/cncr.10489
pubmed: 12015765
Laane E, Bjorklund E, Mazur J, Lonnerholm G, Soderhall S, Porwit A (2007) Dendritic cell regeneration in the bone marrow of children treated for acute lymphoblastic leukaemia. Scand J Immunol 66(5):572–583. https://doi.org/10.1111/j.1365-3083.2007.02007.x
doi: 10.1111/j.1365-3083.2007.02007.x
pubmed: 17892461
Lucas N, Duchmann M, Rameau P, Noel F, Michea P, Saada V et al (2019) Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia 33(10):2466–2480. https://doi.org/10.1038/s41375-019-0447-3
doi: 10.1038/s41375-019-0447-3
pubmed: 30894665
Ma M, Wang X, Tang J, Xue H, Chen J, Pan C et al (2012) Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia. Front Med 6(4):416–420. https://doi.org/10.1007/s11684-012-0224-4
doi: 10.1007/s11684-012-0224-4
pubmed: 23065427
Maecker B, Mougiakakos D, Zimmermann M, Behrens M, Hollander S, Schrauder A et al (2006) Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia 20(4):645–649. https://doi.org/10.1038/sj.leu.2404146
doi: 10.1038/sj.leu.2404146
pubmed: 16498391
Mami NB, Mohty M, Chambost H, Gaugler B, Olive D (2004) Blood dendritic cells in patients with acute lymphoblastic leukaemia. Br J Haematol 126(1):77–80. https://doi.org/10.1111/j.1365-2141.2004.04989.x
doi: 10.1111/j.1365-2141.2004.04989.x
pubmed: 15198735
Menezes J, Acquadro F, Wiseman M, Gomez-Lopez G, Salgado RN, Talavera-Casanas JG et al (2014) Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia 28(4):823–829. https://doi.org/10.1038/leu.2013.283
doi: 10.1038/leu.2013.283
pubmed: 24072100
Milley S, Thomas L, Balme B, Dalle S (2016) Blastic plasmacytoid dendritic cell neoplasm following Waldenstrom macroglobulinemia. J Eur Acad Dermatol Venereol 30(5):904–905. https://doi.org/10.1111/jdv.13074
doi: 10.1111/jdv.13074
pubmed: 25765631
Neumann M, Heesch S, Schlee C, Schwartz S, Gokbuget N, Hoelzer D et al (2013) Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 121(23):4749–4752. https://doi.org/10.1182/blood-2012-11-465138
doi: 10.1182/blood-2012-11-465138
pubmed: 23603912
Petrella T, Facchetti F (2010) Tumoral aspects of plasmacytoid dendritic cells: what do we know in 2009? Autoimmunity 43(3):210–214. https://doi.org/10.3109/08916930903510898
doi: 10.3109/08916930903510898
pubmed: 20166873
Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M et al (2005) Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 123(5):662–675
doi: 10.1309/GJWNPD8HU5MAJ837
Reichard KK, Burks EJ, Foucar MK, Wilson CS, Viswanatha DS, Hozier JC et al (2005) CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol 29(10):1274–1283. https://doi.org/10.1097/01.pas.0000172194.32918.5c
doi: 10.1097/01.pas.0000172194.32918.5c
pubmed: 16160468
Renosi F, Roggy A, Giguelay A, Soret L, Viailly PJ, Cheok M et al (2021) Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Adv 5(5):1540–1551. https://doi.org/10.1182/bloodadvances.2020003359
doi: 10.1182/bloodadvances.2020003359
pubmed: 33687433
pmcid: 7948279
Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal MR et al (1999) Reciprocal control of T helper cell and dendritic cell differentiation. Science 283(5405):1183–1186. https://doi.org/10.1126/science.283.5405.1183
doi: 10.1126/science.283.5405.1183
pubmed: 10024247
Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA et al (2014) Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia 28(8):1606–1616. https://doi.org/10.1038/leu.2014.64
doi: 10.1038/leu.2014.64
pubmed: 24504027
pmcid: 4294271
Sawant A, Hensel JA, Chanda D, Harris BA, Siegal GP, Maheshwari A et al (2012) Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. J Immunol 189(9):4258–4265. https://doi.org/10.4049/jimmunol.1101855
doi: 10.4049/jimmunol.1101855
pubmed: 23018462
Song HL, Huang WY, Chen YP, Chang KC (2012) Tumorous proliferations of plasmacytoid dendritic cells and Langerhans cells associated with acute myeloid leukaemia. Histopathology 61(5):974–983. https://doi.org/10.1111/j.1365-2559.2012.04282.x
doi: 10.1111/j.1365-2559.2012.04282.x
pubmed: 22804228
Sozzani S, Vermi W, Del Prete A, Facchetti F (2010) Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends Immunol 31(7):270–277. https://doi.org/10.1016/j.it.2010.05.004
doi: 10.1016/j.it.2010.05.004
pubmed: 20579936
Steven H, Swerdlow EC, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R (2017) WHO Classification of tumours of haematopoietic and lymphoid tissues (Revised, 4th edn. International Agency for Research on Cancer, Lyon, France
Tang Z, Tang G, Wang SA, Lu X, Young KH, Bueso-Ramos CE et al (2016) Simultaneous deletion of 3’ETV6 and 5’EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review. Mol Cytogenet 9:23. https://doi.org/10.1186/s13039-016-0232-1
doi: 10.1186/s13039-016-0232-1
pubmed: 26925167
pmcid: 4769509
Tang Z, Li Y, Wang W, Yin CC, Tang G, Aung PP et al (2018) Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. Leuk Res 73:86–94. https://doi.org/10.1016/j.leukres.2018.09.006
doi: 10.1016/j.leukres.2018.09.006
pubmed: 30248580
Trimoreau F, Donnard M, Turlure P, Gachard N, Bordessoule D, Feuillard J (2003) The CD4+ CD56+ CD116- CD123+ CD45RA+ CD45RO- profile is specific of DC2 malignancies. Haematologica 88(3):ELT10
pubmed: 12651292
Triplett TA, Cardenas KT, Lancaster JN, Hu Z, Selden HJ, Jasso GJ et al (2016) Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation. Proc Natl Acad Sci U S A 113(8):E1016-1025. https://doi.org/10.1073/pnas.1520245113
doi: 10.1073/pnas.1520245113
pubmed: 26862168
pmcid: 4776467
Vermi W, Facchetti F, Rosati S, Vergoni F, Rossi E, Festa S et al (2004) Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes/interferon-producing cells associated with myeloid disorders. Am J Surg Pathol 28(5):585–595. https://doi.org/10.1097/00000478-200405000-00004
doi: 10.1097/00000478-200405000-00004
pubmed: 15105645
Vitte F, Fabiani B, Benet C, Dalac S, Balme B, Delattre C et al (2012) Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. Am J Surg Pathol 36(9):1302–1316. https://doi.org/10.1097/PAS.0b013e31825dd4de
doi: 10.1097/PAS.0b013e31825dd4de
pubmed: 22895265
Wang M, Chen YJ, Wang LR, Wang YZ, Lu J (2018) Plasmacytoid dendritic cells proliferation coexisted with acute myeloid leukemia. Chin Med J 131(15):1866–1867. https://doi.org/10.4103/0366-6999.237404
doi: 10.4103/0366-6999.237404
pubmed: 30058585
pmcid: 6071469
Wang P, Feng Y, Deng X, Liu S, Qiang X, Gou Y et al (2017) Tumor-forming plasmacytoid dendritic cells in acute myelocytic leukemia: a report of three cases and literature review. Int J Clin Exp Pathol 10(7):7285–7291
pubmed: 31966568
pmcid: 6965252
Xiao W, Goldberg AD, Famulare CA, Devlin SM, Nguyen NT, Sim S et al (2019) Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia. Haematologica 104(7):1378–1387. https://doi.org/10.3324/haematol.2018.203018
doi: 10.3324/haematol.2018.203018
pubmed: 30523054
pmcid: 6601104
Xiao W, Chan A, Waarts MR, Mishra T, Liu Y, Cai SF et al (2021) Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood 137(10):1377–1391. https://doi.org/10.1182/blood.2020007897
doi: 10.1182/blood.2020007897
pubmed: 32871587
pmcid: 7955409
Yang GX, Lian ZX, Kikuchi K, Moritoki Y, Ansari AA, Liu YJ et al (2005) Plasmacytoid dendritic cells of different origins have distinct characteristics and function: studies of lymphoid progenitors versus myeloid progenitors. J Immunol 175(11):7281–7287. https://doi.org/10.4049/jimmunol.175.11.7281
doi: 10.4049/jimmunol.175.11.7281
pubmed: 16301633
Yu H, Zhang P, Yin X, Yin Z, Shi Q, Cui Y et al (2015) Human BDCA2+CD123+CD56+ dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset. Protein Cell 6(4):297–306. https://doi.org/10.1007/s13238-015-0140-x
doi: 10.1007/s13238-015-0140-x
pubmed: 25779340
pmcid: 4383756
Zalmai L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F et al (2021) Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica 106(12):3056–3066. https://doi.org/10.3324/haematol.2020.253740
doi: 10.3324/haematol.2020.253740
pubmed: 33054115
Zhou Z, Lin W, Li X, Huang Y, Ren J, Gao Y et al (2019) Aberrant phenotype and function of dendritic cells in adult B lineage acute lymphoblastic leukemia. Immunol Invest 48(8):781–793. https://doi.org/10.1080/08820139.2019.1610428
doi: 10.1080/08820139.2019.1610428
pubmed: 31062637
Zhu L, Wang P, Zhang W, Li Q, Xiong J, Li J et al (2020) Plasmacytoid dendritic cell infiltration in acute myeloid leukemia. Cancer Manag Res 12:11411–11419. https://doi.org/10.2147/CMAR.S260825
doi: 10.2147/CMAR.S260825
pubmed: 33192098
pmcid: 7654521